Drug research boosts Wuxi PharmaTech

In his The China Stock Digest, he explains, "In a nutshell, WuXi performs pharmaceutical R&D on a contract basis for paying clients; it provides services to nine of the top ten pharma companies in the world."

"\WuXi PharmaTechprovides laboratory and manufacturing services throughout the drug and medical device R&D process to pharmaceutical, biotechnology and medical device companies worldwide.

"Because Chinese researchers receive much smaller paychecks than their Western counterparts, WuXi is able to assist its global partners in shortening the drug discovery cycle and lowering the cost of drug and medical device R&D.

"Although WuXi has deep expertise in biotechnology, there’s no need to be concerned about the risky and failure-prone arena of entrepreneurial drug discovery.

"WuXi has more than 3,300 employees in China and several U.S. cities. The firm’s senior management team consists of Ph.D.s and MBAs; management has more than 200 patents pending or granted, and has published more than 800 scientific publications.

"WuXi’s U.S.-based facilities are all FDA-registered, including a 63,000 square-foot R&D and manufacturing facility in St. Paul, Minnesota, a 46,000 square-foot testing facility in Atlanta, and a 75,000 square-foot R&D and testing and manufacturing facility in Philadelphia.

"WuXi boasts that most of its customers return to the firm after the completion of a research contract for additional and often larger and longer-term projects.

"Indeed, each of WuXi’s top 10 customers over the last three years continues to be its customer today, a fact that speaks well of the firm’s skill, efficiency . . .

For access to the full article, you must be a registered member - it's FREE.

Already a member? Please log in below